EUVIMEDEUVIMED entdecken
Crossref

Treatment of severe atopic dermatitis with tralokinumab in clinical practice: short-term effectiveness and safety results

José-Juan Pereyra-Rodríguez iD, Pedro Herranz, Ricardo Ruiz-Villaverde iD, Marta Elosua-González, Manuel Galán-Gutiérrez, Ignasi Figueras-Nart, Javier Miquel, Pablo de la Cueva, Esther Serra-Baldrich, Monica Munera-Campos, Gemma Melé-Ninot, Vicente Expósito-Serrano und 4 weitere

Clinical and Experimental Dermatology · 2023

DOI: 10.1093/ced/llad153 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, 2023. Verfasst von José-Juan Pereyra-Rodríguez und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University Hospital Virgen del Roco University Hospital, Sevilla, Spain. Hauptthemen laut MEDLINE: Dermatitis, Atopic. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tralokinumab was recently approved for the treatment of moderate-to-severe atopic dermatitis (AD) and is the first selective interleukin (IL)-13 inhibitor that specifically neutralizes IL-13 with high affinity.

Objectives

To determine the real-life short-term effectiveness and safety of tralokinumab treatment in patients with moderate-to-severe AD.

Methods

A multicentre retrospective study was conducted including adult patients with moderate-to-severe AD who started tralokinumab treatment from 1 April to 30 June 2022 in 16 Spanish hospitals. Demographic and disease characteristics, severity and quality of life scales were collected at the baseline visit and at weeks 4 and 16.

Results

Eighty-five patients were included. Twenty-seven patients (32%) were non-naive to advanced therapy (biological or Janus kinase inhibitors inhibitors). All included patients had severe disease with baseline Eczema Area and Severity Index (EASI) scores of 25.4 (SD 8.1), Dermatology Life Quality Index (DLQI) 15.8 (5.4) and peak pruritus numerical rating scale (PP-NRS) 8.1 (1.8) and 65% had an Investigator’s Global Assessment (IGA) of 4. At week 16, there was improvement on all scales. The mean EASI decreased to 7.5 (SD 6.9, 70% improvement), SCORing Atopic Dermatitis improved 64% and PP-NRS, 57%. Also, 82%, 58% and 21% of the patients achieved EASI 50, 75 and 90, respectively. The percentage of EASI 75 responders was significantly higher among the naive vs. non-naive groups (67% vs. 41%). The safety profile was acceptable.

Conclusions

Patients, with a long history of disease and prior multidrug failure, showed a good response to tralokinumab, confirming clinical trial results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicAdultHumansQuality of LifeRetrospective StudiesTreatment OutcomePruritusSeverity of Illness IndexDouble-Blind MethodAntibodies, Monoclonal

Substanzen

tralokinumabAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Dermatology, University Hospital Virgen del Roco University Hospital, Sevilla, Spain.
  • Department of Dermatology, University Hospital La Paz, Madrid, Spain.
  • Department of Dermatology, University Hospital San Cecilio, Instituto biosanitario de Granada, Ibs, Granada, Spain.
  • Department of Dermatology, University Hospital Puerta del Hierro, Madrid, Spain.
  • Department of Dermatology, University Hospital, Córdoba, Spain.
  • Department of Dermatology, University Hospital de Bellvitge, Barcelona, Spain.

ORCID-Profile: José-Juan Pereyra-Rodríguez, Ricardo Ruiz-Villaverde

Zitieren

APA

Pereyra-Rodríguez, J. J., Herranz, P., Ruiz-Villaverde, R., Elosua-González, M., Galán-Gutiérrez, M., Figueras-Nart, I., Miquel, J., de la Cueva, P., Serra-Baldrich, E., Munera-Campos, M., Melé-Ninot, G., Expósito-Serrano, V., Perez, B., Serrano, A., Ortiz de Frutos, J. F., & Armario-Hita, J. C. (2023). Treatment of severe atopic dermatitis with tralokinumab in clinical practice: short-term effectiveness and safety results. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llad153

Vancouver

Pereyra-Rodríguez JJ, Herranz P, Ruiz-Villaverde R, Elosua-González M, Galán-Gutiérrez M, Figueras-Nart I, et al. Treatment of severe atopic dermatitis with tralokinumab in clinical practice: short-term effectiveness and safety results. Clinical and Experimental Dermatology. 2023. doi:10.1093/ced/llad153

BibTeX
@article{PereyraRodrguez2023,
  author = {Pereyra-Rodríguez, José-Juan and Herranz, Pedro and Ruiz-Villaverde, Ricardo and Elosua-González, Marta and Galán-Gutiérrez, Manuel and Figueras-Nart, Ignasi and Miquel, Javier and de la Cueva, Pablo and Serra-Baldrich, Esther and Munera-Campos, Monica and Melé-Ninot, Gemma and Expósito-Serrano, Vicente and Perez, Bibiana and Serrano, Amalia and Ortiz de Frutos, Javier F and Armario-Hita, José C},
  title = {Treatment of severe atopic dermatitis with tralokinumab in clinical practice: short-term effectiveness and safety results},
  journal = {Clinical and Experimental Dermatology},
  year = {2023},
  doi = {10.1093/ced/llad153}
}
Kostenlos starten →